Skip to main content
. Author manuscript; available in PMC: 2018 Oct 2.
Published in final edited form as: Mol Pharm. 2017 Aug 30;14(10):3391–3398. doi: 10.1021/acs.molpharmaceut.7b00420

Figure 4.

Figure 4

Biodistribution of 64Cu-DOTA-Pab-IR800 and 64Cu-DOTA-IgG in mice bearing NCI/ADR-RES xenograft. Mice were injected with 64Cu-DOTA-Pab-IR800 and 64Cu-DOTA-IgG, and were sacrificed 48h post injection. Tissues and organs of interest were excised and weighed. Radioactivity was measured and the tracer uptake was calculated as %ID/g. The tumor uptake of 64Cu-DOTA-Pab-IR800 was significantly higher than that of 64Cu-DOTA-IgG at 48 h post injection